Risperidone

Generic Name: Risperidone

Brand Names: Perseris, Risperdal, Rykindo, Uzedy, Okedi

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇FN_₄O_₂

CAS Number: 106266-06-2

Unique Ingredient Identifier: L6UH7ZF8HC

Background: Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...

Indication: Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...

Associated Conditions: Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Associated Therapies: -

Clinical Trials

Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders

Phase 1

Conditions: Visual Perceptual Weakness
Social Behavior
EEG With Periodic Abnormalities
Fluency Disorder
Attention

Interventions: Drug: Risperidone
Device: tDCS or Transcranial Direct Current Stimulation

First Posted Date: 2024-04-16

Last Posted Date: 2024-05-07

Lead Sponsor: Spanish Foundation for Neurometrics Development

Target Recruit Count: 180

Registration Number: NCT06368726

Locations: 🇬🇧
New Remedies, Liverpool, Merseyside, United Kingdom

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

Phase 4

Recruiting

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole
Drug: Risperidone

First Posted Date: 2024-02-01

Last Posted Date: 2024-12-19

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 60

Registration Number: NCT06236451

Locations: 🇮🇳
All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India

Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

Not Applicable

Completed

Conditions: Antipsychotics and Neuroleptics Toxicity

Interventions: Drug: Risperidone
Drug: Olanzapine
Drug: Quetiapine
Drug: Risperidone and Vitamin D and Vitamin E
Drug: Olanzapine and Vitamin D and Vitamin E
Drug: Quetiapine and Vitamin D and Vitamin E

First Posted Date: 2024-01-11

Last Posted Date: 2024-01-11

Lead Sponsor: Dr Rabia Arshad

Target Recruit Count: 140

Registration Number: NCT06200584

Locations: 🇵🇰
Jinnah Post Graduate Medical Centre, Karachi, Sindh, Pakistan

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

Phase 4

Terminated

Conditions: Psychosis

Interventions: Drug: Lumateperone
Drug: Risperidone

First Posted Date: 2023-06-06

Last Posted Date: 2024-06-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 5

Registration Number: NCT05890768

Locations: 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

Phase 3

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Drug: LYN-005
Drug: Risperidone

First Posted Date: 2023-03-22

Last Posted Date: 2024-10-24

Lead Sponsor: Lyndra Inc.

Target Recruit Count: 83

Registration Number: NCT05779241

Locations: 🇺🇸
CenExel CNS, Garden Grove, California, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Uptown Research Institute, Chicago, Illinois, United States

and more 2 locations

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Phase 2

Not yet recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Risperidone
Drug: Pramipexole

First Posted Date: 2022-06-02

Last Posted Date: 2022-06-02

Lead Sponsor: Clinical Academic Center (2CA-Braga)

Target Recruit Count: 52

Registration Number: NCT05401019

Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome

Not Applicable

Terminated

Conditions: 22q11.2 Deletion Syndrome

Interventions: Drug: Placebo
Drug: Risperdal

First Posted Date: 2020-11-23

Last Posted Date: 2024-12-06

Lead Sponsor: University of Geneva, Switzerland

Target Recruit Count: 16

Registration Number: NCT04639960

Locations: 🇨🇭
Developmental imaging and psychopathology lab, Geneva, Switzerland

Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: MK-8189
Drug: Risperidone
Drug: Placebo to risperidone
Drug: Placebo to MK-8189

First Posted Date: 2020-11-10

Last Posted Date: 2024-07-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 500

Registration Number: NCT04624243

Locations: 🇺🇸
Pillar Clinical Research, LLC ( Site 1038), Chicago, Illinois, United States
🇺🇸
Richmond Behavioral Associates ( Site 1064), Staten Island, New York, United States
🇺🇸
Massachusetts General Hospital ( Site 1035), Boston, Massachusetts, United States

and more 118 locations

Reducing the Abuse Liability of Prescription Opioids

Early Phase 1

Completed

Conditions: Addiction

Interventions: Drug: Risperidone
Drug: Ziprasidone
Drug: Oxycodone

First Posted Date: 2020-10-14

Last Posted Date: 2020-10-14

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 15

Registration Number: NCT04587115

Locations: 🇺🇸
Westgate Pain Clinic, San Antonio, Texas, United States

CLOZAPINE Response in Biotype-1

Phase 4

Recruiting

Conditions: Schizoaffective Disorder
Bipolar 1 Disorder
Schizophrenia

Interventions: Drug: clozapine
Drug: risperidone

First Posted Date: 2020-10-08

Last Posted Date: 2024-08-28

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 524

Registration Number: NCT04580134

Locations: 🇺🇸
Hartford Healthcare, Hartford, Connecticut, United States
🇺🇸
University of Georgia, Athens, Georgia, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy